Perceptive Capital Solutions Corp. is a blank-check company, or special purpose acquisition company (SPAC), incorporated in the Cayman Islands and headquartered in New York. The company was sponsored by an affiliate of Perceptive Advisors, a prominent life sciences-focused investment firm, to identify and merge with a high-growth business in the healthcare sector, specifically targeting life sciences and medical technology companies in North America and Europe. PCSC completed its initial public offering in June 2024, raising $86.25 million. As a pre-deal SPAC, the company does not have active business operations and generates revenue solely from interest income on the proceeds held in its trust account. On December 5, 2025, PCSC announced a definitive business combination agreement with Freenome Holdings, Inc., a clinical-stage biotechnology company that utilizes a multiomics platform and machine learning to develop non-invasive, blood-based screening tests for the early detection of cancer. Upon the expected closing of the transaction in the first half of 2026, PCSC will redomicile to Delaware, rename itself to Freenome, Inc., and trade on the Nasdaq under the ticker symbol 'FRNM'.
